Annual report pursuant to Section 13 and 15(d)

OPERATING BUSINESS SEGMENT AND INTERNATIONAL OPERATION INFORMATION

v2.4.1.9
OPERATING BUSINESS SEGMENT AND INTERNATIONAL OPERATION INFORMATION
12 Months Ended
Dec. 31, 2014
Segment Information  
OPERATING BUSINESS SEGMENT AND INTERNATIONAL OPERATION INFORMATION

 

NOTE 14:  OPERATING BUSINESS SEGMENT AND INTERNATIONAL OPERATION INFORMATION

 

The Company has four business segments. These business segments are components of the Company for which separate information is available that is evaluated regularly by the chief executive officer in deciding how to allocate resources and in assessing relative performance.

 

The Company has two business segments that operate under the Nature’s Sunshine® Products brand and are divided based on the characteristics of their Distributor base, similarities in compensation plans, as well as the internal organization of NSP’s officers and their responsibilities (NSP Americas and NSP Russia, Central and Eastern Europe). The Company’s third business segment operates under the Synergy® WorldWide brand, which distributes its products through different selling and Distributor compensation plans and has products with formulations that are sufficiently different from those of NSP Americas and NSP Russia, Central and Eastern Europe to warrant accounting for these operations as a separate business segment. The Company’s fourth business segment, China and New Markets, anticipates deploying a multi-brand, multi-channel go-to-market strategy that offers select Nature’s Sunshine branded products through Fosun Pharma’s retail locations across China as well as ecommerce, and select Synergy branded products through a direct selling model.  The time to market will be dependent upon regulatory processes including product registration and permit approvals. The China and New Markets segment also includes Company’s export sales business, in which the Company sells our products to various locally managed entities independent of the Company that have distribution rights for the relevant market. All of the net sales revenue to date in the China and New Markets segment is through the Company’s export business to foreign markets outside of China set forth above that were previously part of NSP Americas. Net sales revenues for each segment have been reduced by intercompany sales as they are not included in the measure of segment profit or loss reviewed by the chief executive officer. The Company evaluates performance based on contribution margin (loss) by segment before consideration of certain inter-segment transfers and expenses.

 

In the fourth quarter of 2014, the Company created the China and New Markets segment. The Company moved the reporting of its export business, in which the Company sells our products to a locally managed entity independent of the Company that has distribution rights for the market, from the NSP Americas segment to the China and New Markets segment during the year ended December 31, 2014, and has made conforming changes to the results presented above for the prior year periods. The net sales revenue and contribution margin of this business for the year ended December 31, 2014 were $3,367 and 1,563, respectively. The net sales revenue and contribution margin of this business for the year ended December 31, 2013 were $2,865 and $1,318, respectively. The net sales revenue and contribution margin of this business for the year ended December 31, 2012 were $2,509 and $159, respectively.

 

Reportable business segment information for the years ended December 31, 2014, 2013 and 2012 is as follows:

 

Year Ended December 31,

 

2014

 

2013

 

2012

 

Net sales revenue:

 

 

 

 

 

 

 

NSP Americas

 

$

184,625

 

$

195,924

 

$

199,794

 

NSP Russia, Central and Eastern Europe

 

50,274

 

62,747

 

57,853

 

Synergy WorldWide

 

128,101

 

108,290

 

100,670

 

China and New Markets

 

3,367

 

2,865

 

2,509

 

Total net sales revenue

 

366,367

 

369,826

 

360,826

 

Contribution margin (1):

 

 

 

 

 

 

 

NSP Americas

 

75,673

 

80,095

 

80,324

 

NSP Russia, Central and Eastern Europe

 

17,851

 

22,542

 

21,957

 

Synergy WorldWide

 

43,888

 

38,011

 

36,142

 

China and New Markets

 

1,563

 

1,318

 

159

 

Total contribution margin

 

138,975

 

141,966

 

138,582

 

 

 

 

 

 

 

 

 

Selling, general and administrative

 

119,927

 

118,383

 

104,716

 

Operating income

 

19,048

 

23,583

 

33,866

 

 

 

 

 

 

 

 

 

Other income (loss), net

 

(34

)

1,993

 

1,573

 

Income from continuing operations before provision for income taxes

 

$

19,014

 

$

25,576

 

$

35,439

 

 

(1)

Contribution margin consists of net sales revenue less cost of sales and volume incentives expense.

 

Year Ended December 31,

 

2014

 

2013

 

2012

 

Capital expenditures:

 

 

 

 

 

 

 

NSP Americas

 

$

25,581 

 

$

8,018 

 

$

5,684 

 

NSP Russia, Central and Eastern Europe

 

 

 

44 

 

Synergy WorldWide

 

1,321 

 

534 

 

1,051 

 

China and New Markets

 

 

 

 

Total capital expenditures

 

$

26,910 

 

$

8,556 

 

$

6,779 

 

 

 

 

 

 

 

 

 

Depreciation and amortization:

 

 

 

 

 

 

 

NSP Americas

 

$

3,438 

 

$

3,568 

 

$

3,339 

 

NSP Russia, Central and Eastern Europe

 

25 

 

27 

 

36 

 

Synergy WorldWide

 

946 

 

871 

 

703 

 

China and New Markets

 

 

 

 

Total depreciation and amortization

 

$

4,409 

 

$

4,466 

 

$

4,078 

 

 

As of December 31,

 

2014

 

2013

 

Assets:

 

 

 

 

 

NSP Americas

 

$

129,371 

 

$

148,278 

 

NSP Russia, Central and Eastern Europe

 

6,679 

 

11,233 

 

Synergy WorldWide

 

40,797 

 

40,101 

 

China and New Markets

 

19,952 

 

 

Total assets

 

$

196,799 

 

$

199,612 

 

 

From an individual country perspective, only the United States comprises approximately 10 percent or more of consolidated net sales revenue for any of the years ended December 31, 2014, 2013 and 2012 as follows:

 

Year Ended December 31,

 

2014

 

2013

 

2012

 

Net sales revenue:

 

 

 

 

 

 

 

United States

 

$

148,219 

 

$

152,209 

 

$

154,716 

 

South Korea

 

54,314 

 

34,207 

 

28,006 

 

Other

 

163,834 

 

183,410 

 

178,104 

 

Total net sales revenue

 

$

366,367 

 

$

369,826 

 

$

360,826 

 

 

Revenue generated by each of the Company’s product lines is set forth below (U.S. dollars in thousands):

 

Year Ended December 31,

 

2014

 

2013

 

2012

 

NSP Americas:

 

 

 

 

 

 

 

General health

 

$

79,022 

 

$

82,332 

 

$

87,280 

 

Immunity

 

23,881 

 

24,013 

 

24,410 

 

Cardiovascular

 

12,665 

 

13,268 

 

13,483 

 

Digestive

 

53,906 

 

57,575 

 

56,160 

 

Personal care

 

4,025 

 

5,214 

 

5,792 

 

Weight management

 

11,126 

 

13,522 

 

12,669 

 

 

 

184,625 

 

195,924 

 

199,794 

 

NSP Russia, Central and Eastern Europe:

 

 

 

 

 

 

 

General health

 

$

18,841 

 

$

22,690 

 

$

20,540 

 

Immunity

 

6,512 

 

7,902 

 

7,365 

 

Cardiovascular

 

3,104 

 

4,324 

 

4,367 

 

Digestive

 

13,171 

 

15,693 

 

14,501 

 

Personal care

 

6,073 

 

8,817 

 

8,908 

 

Weight management

 

2,573 

 

3,321 

 

2,172 

 

 

 

50,274 

 

62,747 

 

57,853 

 

Synergy WorldWide:

 

 

 

 

 

 

 

General health

 

$

46,546 

 

$

36,723 

 

$

33,969 

 

Immunity

 

974 

 

1,394 

 

1,104 

 

Cardiovascular

 

42,449 

 

42,154 

 

42,696 

 

Digestive

 

20,839 

 

16,897 

 

14,904 

 

Personal care

 

7,196 

 

7,097 

 

5,631 

 

Weight management

 

10,097 

 

4,025 

 

2,366 

 

 

 

128,101 

 

108,290 

 

100,670 

 

China and New Markets:

 

 

 

 

 

 

 

General health

 

$

1,566 

 

$

1,306 

 

$

1,180 

 

Immunity

 

445 

 

367 

 

319 

 

Cardiovascular

 

235 

 

211 

 

188 

 

Digestive

 

835 

 

726 

 

632 

 

Personal care

 

83 

 

74 

 

70 

 

Weight management

 

203 

 

181 

 

120 

 

 

 

3,367 

 

2,865 

 

2,509 

 

Total net sales revenue

 

$

366,367 

 

$

369,826 

 

$

360,826 

 

 

From an individual country perspective, only the United States and Venezuela comprise 10 percent or more of consolidated property, plant and equipment as follows:

 

As of December 31 

 

2014

 

2013

 

Property, plant and equipment

 

 

 

 

 

United States

 

$

48,013 

 

$

25,713 

 

Venezuela

 

 

3,207 

 

Other

 

3,330 

 

3,102 

 

Total property, plant and equipment

 

$

51,343 

 

$

32,022 

 

 

Due to the continual currency devaluation of the Venezuelan bolivar, as of September 30, 2014, the Company incurred a $2,947 impairment charge to write down the value of its fixed assets in Venezuela to $0.